Trial Profile
The effect of a once daily evening dose of atomoxetine (ATX) on ADHD [attention-deficit hyperactivity disorder]-related insomnia in children and adolescents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder; Insomnia
- Focus Therapeutic Use
- 13 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2008 The expected completion date for this trial is now 1 Jun 2009 according to ClinicalTrials.gov.